In Trading, Results Matter.
Our Top 10 exits in last 5 trading days.

bluebird bio, Inc.. Trade Record

NASDAQ:BLUE bluebird bio, Inc. stock gains 30.22% Exit Jun 23, 2017 a Trade Record by priceseries

Trade Chart
Trade Chart BLUE Jun 2, 2017, priceSeries
About bluebird bio, Inc.

bluebird bio, Inc., a clinical-stage biotechnology company, focuses on developing transformative gene therapies for severe genetic diseases and cancer. Its product candidates include Lenti-D that is in phase II/III clinical studies for the treatment of cerebral adrenoleukodystrophy, a rare hereditary neurological disorder; and LentiGlobin, which is in four clinical studies for the treatment of transfusion-dependent beta-thalassemia, and severe sickle cell disease. The company's lead product candidate is bb2121, a chimeric antigen receptor T cell product candidate that is in Phase I trial for the treatment of relapsed/refractory multiple myeloma. bluebird bio, Inc. has a strategic collaboration with Celgene Corporation to discover, develop, and commercialize disease-altering gene therapies in oncology; Kite Pharma, Inc. to develop and commercialize second generation T cell receptor (TCR) product candidates against an antigen related to certain cancers associated with the human papilloma virus; and Medigene AG for the research and development of TCR product candidates directed against approximately four antigens for the treatment of cancer indications. The company was formerly known as Genetix Pharmaceuticals, Inc., and changed its name to bluebird bio, Inc. in September 2010. bluebird bio, Inc. was founded in 1992 and is headquartered in Cambridge, Massachusetts.

Trade Information
Trade Type
LONG
ReliabilityScore™
98.18
Entry Date
Jun 2, 2017
Entry Price
84.15
Sell Date
Jun 23, 2017
Sell Price
109.58
Net Gain
30.22%
Hold Time
15 Trading Days